In a blow to the drug maker and millions of overweight and obese Americans hoping for a new weight-loss medication, the FDA’s Endocrinologic and Metabolic Drugs Advisory Committee unanimously told Sanofi-Aventis to gather more detailed safety information about rimonabant over the long term, in larger patient numbers.

Insufficient numbers of women who had gestational diabetes during pregnancy are being screened for diabetes in the first year postpartum, according to a retrospective study.

An experimental drug prevented mice from developing diabetes and heart disease and might one day be used to stave off the diseases in humans, U.S. researchers said last week.

In patients with type 2 diabetes, the risk of a first coronary heart disease (CHD) event depends on a number of factors, including sex, age, and microvascular disease, as well as glycemic control and dyslipidemia.

Findings from an interim analysis of RECORD (Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of glycemia in Diabetes), shows further proof the safety of Avandia.

The FDA Commissioner Andrew C. von Eschenbach, M.D., told a congressional hearing that the FDA will beef up the cardiovascular warnings on the labels of both rosiglitazone (Avandia) and pioglitazone (Actos).

Merck & Co., Inc. announced that the U.S. Food and Drug Administration (FDA) approved JANUMET™, the first and only tablet combining a dipeptidyl peptidase-4 (DPP-4) inhibitor, sitagliptin (also known as JANUVIA™), and metformin for the treatment of type 2 diabetes.

Study shows that insulin resistant can be an independent risk factor for cardiovascular disease.

Positive results are dependent upon BMI at start of therapy

A new once-weekly formulation of exenatide improves glycemic control and fosters weight loss in patients with type 2 diabetes, according to a new report.